Leustat (Cladribine)

Cladribine is a purine nucleoside analog that enters lymphocytes and is phosphorylated to an active triphosphate. This metabolite is incorporated into DNA, disrupting synthesis and repair, which triggers programmed cell death (apoptosis) of both malignant and normal lymphocytes.

The dosing regimen for Leustat is determined by the prescribing physician based on the patient’s weight, disease status, and laboratory parameters. Clinicians follow approved guidelines and adjust the schedule according to individual response and tolerability.

Safety of cladribine during pregnancy or lactation has not been established. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit outweighs the risk, and decisions should be made in consultation with a healthcare professional.

To order Leustat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Leustat (cladribine) belongs to the purine nucleoside analog class, similar to pentostatin. Compared with pentostatin, cladribine has a longer intracellular half‑life and may be administered in fewer cycles, but both share comparable efficacy in hairy cell leukemia and similar hematologic toxicity profiles.

Leustat must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect from light, and do not freeze or shake the product. If temperature excursions occur, discard the affected units according to the supplier’s guidelines.

Leustat is administered by intravenous infusion under the supervision of a qualified healthcare professional. The infusion is typically given over a defined period, repeated in cycles as prescribed, with monitoring of vital signs and laboratory parameters before, during, and after each administration.

The most serious risks include severe neutropenia leading to life‑threatening infections, opportunistic infections (e.g., fungal or viral), secondary malignancies, and autoimmune hemolytic anemia. Patients should be monitored closely for signs of infection, bleeding, or unexpected laboratory abnormalities.

Leustat should be avoided in patients with active uncontrolled infections, known hypersensitivity to cladribine or any excipients, severe immunosuppression, and in pregnant or breastfeeding women unless absolutely necessary. Clinicians must assess each individual’s medical history before initiating therapy.